Advances in our understanding of the pathogenesis of rheumatic diseases such as
rheumatoid arthritis and systemic lupus erythematosus have led to the emergence of …

There is no simple answer to the question: intravenous immunoglobulin—take it or leave it?
A thorough review of the current data on mechanisms of action, efficacy, and safety of …

Prepared from the collective plasma of several thousand people, therapeutic intravenous
immunoglobulin (IVIg) consists mostly of human polyspecific IgG. In addition to its use in …

Immunoglobulins (antibodies) are plasma proteins produced by B cells, which are essential
in the defence against bacterial and viral infections. Dysregulation of the immune system …

Monoclonal antibodies have proved to be extremely valuable additions to conventional
treatment for rheumatic diseases. However, despite the general trend towards …

Monoclonal antibodies bind to their targets with high specificity and therefore have excellent
potential as therapeutic agents. Biotechnological advances have allowed the production of …

Intravenous immunoglobulins (IVIGs) are beneficial and safe for various diseases other than
primary immunodeficiencies. Over the years, IVIG has been given for autoimmune diseases …

The main goal of antigen-specific immunotherapy (ASI) in autoimmune and rheumatic
diseases is to reprogramme or remove autoreactive cells and/or induce immune tolerance to …

Present treatments for rheumatic diseases are both toxic to patients and largely ineffective in
modifying the disease process. This report, based on a meeting recently held in London …

For many years, non-steroidal anti-inflammatory agents, steroids and immunosuppressive
drugs have been the mainstay of treatment for rheumatological disorders. Over the last few …